date:Sep 27, 2013
tterns between quarters.
Performance Materials is expected to show improved results in 2013, despite the negative effects of caprolactam.
Polymer Intermediates is expected to show lower results than in 2012.
For the Innovation Center the result of the second half of 2013 is expected to be in line with the second half of 2012.
Overall, DSM expects a significant increase in EBITDA during 2013 from the 1.1 billion realized in 2012. This is a result of stronger organic growth, supported by DSMs Pro